Natural product-derived therapy for glucose homeostasis and TIIDM: β-Cryptoxanthin, isolated from sweet peppers, increases Barr2 expression, augments the functional activity of CAMKII, increases insulin secretion, promotes glucose homeostasis, prevents progression to TIIDM and ameliorates obesity-associated metabolic deficits via down regulation of its target gene, 28/July/2017, 10.12 pm

Natural product therapy for glucose homeostasis and TIIDM: Artemether, a derivative of Artemisinin isolated from Artemesia Annua L,   increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 28/July/2017, 10.00 pm
July 28, 2017
Molecular therapy for glioblastoma: MiRNA-766  inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 28/July/2017,  10.57 pm
July 28, 2017
Show all

Introduction: What they say

A study from the Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA shows that “ß-arrestin-2 is an essential regulator of pancreatic ß-cell function under physiological and pathophysiological conditions.” This research paper was published in the 1 February 2017 issue of the journal “Nature communications” [One of the best research journals in General Science with an I.F of 11.329] by Prof. Wess J Dor and Zhu L and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for glucose homeostasis and TIIDM: β-Cryptoxanthin, isolated from sweet peppers, increases Barr2 expression, augments the functional activity of CAMKII, increases insulin secretion, promotes glucose homeostasis, prevents progression to TIIDM and ameliorates obesity-associated metabolic deficits via down regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

Prof. Wess’s research team has recently shown that deletion of Barr2 (ß-arrestin-2 gene) in adult mice results in (1) impaired insulin release (in response to calorie-rich diet); (2) exacerbated glucose intolerance; (3) impairment of glucose-induced insulin secretion; and (4) impairment of CAMKI (Multi-functional Ser/Thr protein kinase) function. On the other hand, overexpression of Barr2: (1) improves metabolic deficits in mice consuming HFD; and (2) promotes ß-cell function and insulin secretion, suggesting that increasing the expression of Barr-2 may alleviate metabolic deficits in diabetic patients.


From Research findings to Therapeutic opportunity:

This study suggests a Natural product-based therapy for TIIDM and obesity-associated metabolic deficits. β-Cryptoxanthin, by increasing the expression of its target gene, it may increase the expression of Barr2.

Figure 1 Mechanistic insights into how β-Cryptoxanthin functions as an antidiabetic agent. β-Cryptoxanthin, by increasing the expression of Barr2 and the activity of CamKII, it may promote insulin secretion.

 

Thereby, it may: (1) promote glucose-induced insulin secretion; (2) promote proper functioning of L-type Ca2+ channels; (3) promote proper functioning of voltage-dependent Ca2+ channels; (4) promote Ca2+ entry into ß-cells; (5) increase the activity of CAMKII; (6) promote CAMKII-dependent phosphorylation of a number of signalling proteins involved in insulin exocytosis, including Synapsin I; (7) promote CAMKII-dependent insulin secretion; (8) ameliorate HFD-induced metabolic deficits; and (9) promote glucose homeostasis (Fig.1). Thus, pharmacological formulations encompassing ” β-Cryptoxanthin or its analogues either alone or in combination with other drugs” may be used to treat TIIDM and Obesity-associated metabolic deficits/abnormalities.

price-quote[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does  β-Cryptoxanthin increase the expression of Barr2 to promote insulin secretion?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product-derived therapy for glucose homeostasis and TIIDM: β-Cryptoxanthin, isolated from sweet peppers, increases Barr2 expression, augments the functional activity of CAMKII, increases insulin secretion, promotes glucose homeostasis, prevents progression to TIIDM and ameliorates obesity-associated metabolic deficits via down regulation of its target gene, 28/July/2017, 10.12 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.